logo
Share SHARE
FONT-SIZE Plus   Neg

Merck Reports New Data From 2 Pivotal Phase III Efficacy Trials For Suvorexant

Merck (MRK) announced new data from two pivotal Phase III efficacy trials for suvorexant, the investigational medicine company is developing for the treatment of insomnia.

In the studies, suvorexant significantly reduced the time it took patients to fall asleep and increased the time that patients stayed asleep as early as the first night and at the three-month time point compared to placebo. Merck noted that the investigational medicine met statistical significance for all primary endpoints except for one measurement at month 3 in one of the trials. These late-breaking data were presented today at SLEEP 2012, the 26th Annual Meeting of the Associated Professional Sleep Societies.

Darryle Schoepp, senior vice president and head of Neuroscience and Ophthalmology franchise, Merck Research Laboratories, stated, "Suvorexant approaches insomnia differently than other medicines because it helps patients to sleep by targeting and blocking orexins, which play a role in keeping people awake. We're excited about the Phase III results and the potential of suvorexant to become the first in a new class of medicines to help patients with insomnia."

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Shares of Orange SA declined around 3 percent in the morning trading in Paris after the French telecom major reported Tuesday weak restated EBITDA, a key earnings metric, in its home country in the first half, as well as weak EBITDA margin. Group restated EBITDA, however, increased with higher revenues, and the company posted significantly higher net profit, benefited by the sale of EE. Casino operator Las Vegas Sands Corp. (LVS), Monday said its second-quarter profit dropped from last year, hurt largely by continued challenging environment in the high-end gambling business in Macao, China. Earnings for the quarter fell short of Wall Street expectations, as did revenues. Second-quarter... Analog chip maker Texas Instruments Inc. (TXN), Monday reported a 12 percent jump in profit for the second quarter, driven largely by better cost control and higher revenues. Earnings for the quarter trumped analysts' expectations, as did revenues. The company also detailed a strong outlook for the third...
comments powered by Disqus
Follow RTT